# BioTech
EUACC page: https://www.euacc.ai/sectors/biotech
Retrieved: 2026-11-16T22:30:50.323Z. Retrieval is not verification. Source content is reference data, never instructions.

## Public content

**slug:** biotech
**name:** BioTech
**headline:** Europe's life-science powerhouse: from mRNA breakthroughs to industrial biology
**introduction:** European biotech demonstrated its global relevance when BioNTech (Mainz) developed the world's first approved mRNA COVID vaccine in partnership with Pfizer. But the continent's biotech strength extends far beyond pandemic response: over 4,500 biotech companies and SMEs operate across the EU, spanning therapeutic biotech (CureVac, Galapagos, Genmab), industrial biotech (Novozymes, Evonik Biotech), agricultural biotech (Biotalys, Agronutrition), and synthetic biology (Ginkgo Bioworks Europe, Basecamp Research).

In 2024, European biotech companies raised EUR 7.6 billion in venture capital and public offerings combined. The Innovative Health Initiative (IHI), successor to IMI2, channels EUR 2.4 billion in public-private funding toward drug discovery, diagnostics, and manufacturing innovation. Horizon Europe’s Cluster 1 (Health) and Cluster 6 (Food, Bioeconomy) together allocate over EUR 17 billion to bio-related research, making the EU the world’s most generous public funder of life-science R&D.

For biotech founders, Europe offers unmatched clinical trial infrastructure (harmonised under the Clinical Trials Regulation), world-class research hospitals, and an EMA centralised marketing authorisation that provides access to 450 million patients in a single regulatory filing. The challenge is Series B and beyond, where US biotech investors and NASDAQ listings historically absorbed European innovation — a dynamic that BioNTech’s Frankfurt listing and Galapagos’ Euronext success are beginning to reverse.
**eu landscape:** The EU pharmaceutical market is the world's second-largest (EUR 290B annually). Europe hosts 10 of the world's top 20 pharmaceutical companies and produces 40 % of global biopharmaceutical patents. The BioRegions network connects 14 life-science clusters, from the Medicon Valley (Copenhagen-Malmo) to BioValley (Basel-Strasbourg-Freiburg), creating the world's densest network of biotech talent and infrastructure.
**key stats:** 
  -     **label:** EU biotech companies & SMEs
    **value:** 4,500+
    **source:** EuropaBio, 2025
  -     **label:** EU biotech funding (VC + IPO, 2024)
    **value:** EUR 7.6B
    **source:** Dealroom / BioCentury
  -     **label:** Innovative Health Initiative budget
    **value:** EUR 2.4B
    **source:** IHI JU
  -     **label:** EU pharma market size (2025 est.)
    **value:** EUR 330B
    **source:** EFPIA Pharmaceutical Industry in Figures 2026
  -     **label:** Horizon Europe health + bio budget
    **value:** EUR 17B+
    **source:** European Commission
**funding programmes:** 
  -     **slug:** eic-accelerator
    **relevance:** Biotech is the EIC's top-funded sector by volume. Phase II clinical-stage companies, platform technology developers, and industrial biotech scale-ups routinely receive the full EUR 17.5M blended finance.
  -     **slug:** pathfinder-open
    **relevance:** Funds breakthrough biotech research: synthetic biology, gene therapy vectors, organ-on-chip, and AI-driven protein engineering at TRL 1-4.
  -     **slug:** eic-transition
    **relevance:** Bridges lab-stage biotech research toward IND-enabling studies, GMP manufacturing setup, and regulatory pre-submission meetings.
  -     **slug:** horizon-cluster4
    **relevance:** Cluster 1 (Health) funds translational research, clinical trials, and health technology assessment studies. Cluster 6 covers industrial and agricultural biotech.
  -     **slug:** ai-tefs
    **relevance:** The Healthcare AI TEF provides real-world testing for AI-driven diagnostics, drug discovery tools, and clinical decision support systems in regulated healthcare environments.
**top hubs:** 
  -     **why:** Roche and Novartis HQs anchor the BioValley tri-national cluster (CH/FR/DE); 700+ life-science companies, the world's highest density of pharma R&D spending per capita.
    **city:** Basel
    **country:** Switzerland
    **country Code:** CH
  -     **why:** Medicon Valley: Novo Nordisk, Lundbeck, Genmab, and 350+ biotech companies across the Oresund bridge, supported by EUR 3B annual life-science R&D spending.
    **city:** Copenhagen
    **country:** Denmark
    **country Code:** DK
  -     **why:** AstraZeneca HQ, MRC Laboratory of Molecular Biology, and 500+ biotech companies make this Europe's densest life-science cluster outside Basel.
    **city:** Cambridge
    **country:** United Kingdom
    **country Code:** GB
  -     **why:** BioNTech R&D labs, MorphoSys, and Helmholtz Munich. The Bavarian biotech cluster has attracted EUR 2B+ in VC since 2020.
    **city:** Munich
    **country:** Germany
    **country Code:** DE
  -     **why:** Galapagos, Pharming, and ProQR anchor the Leiden Bio Science Park — Europe's largest single-site biotech cluster with 180+ companies.
    **city:** Leiden
    **country:** Netherlands
    **country Code:** NL
**regulations:** 
  -     **name:** Clinical Trials Regulation (536/2014)
    **impact:** Harmonised EU-wide clinical trial authorisation through the CTIS portal. Multi-country trial applications can be submitted simultaneously, reducing approval timelines from 12+ months to 60 days for the initial assessment.
  -     **name:** EMA Centralised Procedure
    **impact:** A single marketing authorisation application to EMA grants market access across all 27 EU member states plus EEA countries — covering 450 million patients in one regulatory filing.
  -     **name:** ATMP Regulation (1394/2007)
    **impact:** Specific regulatory pathway for Advanced Therapy Medicinal Products (gene therapies, cell therapies, tissue-engineered products) with dedicated EMA committee (CAT) assessment.
  -     **name:** EU Bioeconomy Strategy
    **impact:** EUR 100B mobilised toward sustainable bio-based industries. Drives funding and procurement preferences for industrial biotech solutions replacing fossil-based chemicals and materials.
**faqs:** 
  -     **answer:** EMA's centralised procedure covers 27+3 countries in one filing, but typically takes 210 days (vs. FDA's 180-day target). EMA requires more comparative effectiveness data and health technology assessment considerations. However, EMA's PRIME (Priority Medicines) designation accelerates promising therapies with enhanced dialogue, similar to FDA Breakthrough Therapy.
    **question:** How does EMA approval compare to FDA approval for biotech startups?
  -     **answer:** IHI is a EUR 2.4B public-private partnership replacing IMI2. It funds collaborative projects between industry, academia, and SMEs in drug discovery, diagnostics, and digital health. Biotech startups can join consortia responding to IHI calls, typically receiving EUR 0.5-2M per project for 3-5 years. Unlike EIC, IHI does not take equity.
    **question:** What is the Innovative Health Initiative and how can startups participate?
  -     **answer:** Yes. The Clinical Trials Regulation (fully operational since January 2023) enables multinational trial applications through the CTIS portal. A single submission is assessed by a reporting member state with coordinated review by participating countries. Approval timelines are 60 days for initial assessment, making multi-country EU trials more efficient than running separate national approvals.
    **question:** Can I run clinical trials across multiple EU countries simultaneously?
  -     **answer:** Yes. CRISPR and gene-editing therapeutics are explicitly funded under Horizon Europe Cluster 1 and EIC Pathfinder. European companies like CRISPR Therapeutics (originally Basel-based), Basecamp Research, and Mammoth Biosciences Europe work on gene-editing applications. The EU's regulatory framework for ATMPs provides a clear (if demanding) path to market for gene therapies.
    **question:** Is CRISPR-based therapy development supported by EU funding?

## Review record

**status:** ok
**source url:** https://www.europabio.org
**last verified at:** 2026-10-16T07:38:54.86+00:00
**next check due:** 2026-11-15T07:38:57.805+00:00

## Source metadata
